Truking(SZ:300358)2025-10-29 12:17Financial Performance - In the first nine months of 2025, the company achieved revenue of 3.896 billion CNY, a decrease of 6.6% compared to the same period last year [2] - Net profit attributable to shareholders was 84 million CNY, an increase of 145.11% year-on-year [2] - The third quarter of 2025 saw revenue of 1.479 billion CNY, a year-on-year increase of 10.17%, with net profit rising to 93 million CNY, up 186.19% [2] Strategic Initiatives - The company implemented three core strategies leading to profit growth: 1. Focus on "quality improvement and efficiency enhancement" in domestic operations, leading to significant optimization of profit quality [2] 2. Accelerated international business expansion, with international revenue from domestic subsidiaries significantly increasing [2] 3. Deep implementation of cost reduction and efficiency enhancement strategies, resulting in improved operational efficiency and reduced personnel costs [2][3] International Market Expansion - The company is focusing on five key regions for international market expansion: Southeast Asia, Middle East and Africa, Europe, Americas, and India/Australia [3] - The overseas business has entered a rapid growth phase, with notable breakthroughs in the Middle East, Africa, and Southeast Asia [3] Product Development and Market Position - The company is actively developing its biopharmaceutical consumables business, focusing on three main categories, with significant orders already secured [3] - The pharmaceutical robotics business is aligned with the core pharmaceutical equipment industry, aiming for automation and intelligence upgrades [4] Market Competition and Profitability Outlook - The domestic market remains competitive but is becoming more rational, with a focus on differentiated competition [4] - The company expects a gross profit margin of around 30% for 2025, with potential for steady improvement through high-quality development and cost reduction measures [4]